Hyperbaric Oxygen Therapy for the Brain, Wounds & Longevity: What the 2025–2026 Evidence Shows
Hyperbaric oxygen therapy (HBOT) continues to move from anecdote toward evidence. This clinical brief distills the most recent peer-reviewed literature on HBOT for brain injury, wound healing, cognition and long COVID — the protocols used, the effect sizes reported, and where the signal is still preliminary.
For practitioners fielding the question "does hyperbaric oxygen therapy work?", the honest answer in mid-2026 is condition-dependent. The mechanistic rationale is consistent across indications: pressurizing a patient to 1.5–2.5 atmospheres absolute (ATA) while breathing near-100% oxygen sharply raises dissolved plasma oxygen, driving angiogenesis, modulating neuroinflammation, mobilizing stem cells and influencing the hypoxia-inducible pathways implicated in aging[4].
Brain injury & post-concussion: the strongest emerging signal
A 2025 retrospective cohort of adults carrying persistent post-concussion symptoms from childhood traumatic brain injury reported statistically significant gains across nearly every cognitive domain after a standard course of HBOT — global cognition, memory, executive function, attention and processing speed all improved, with motor skills the lone exception[1]. That pattern echoes a meta-analysis of four controlled studies (250 patients) in which HBOT-treated TBI patients showed significantly better cognition versus baseline[2].
Perhaps most compelling for skeptics: a double-blind, sham-controlled randomized trial in veterans with TBI and PTSD reported a mean symptom-scale improvement of +10.6 points on active HBOT versus +3.6 points on sham[3].
Symptom improvement: active HBOT vs. sham (veteran TBI/PTSD RCT)
Mean change in composite symptom score after a 40-session course.[3]
"Against a pressurized sham arm, active HBOT produced a roughly three-fold larger symptom improvement — the kind of separation that moves a therapy from plausible to promising."
Most neurological HBOT studies use 1.5–2.0 ATA, 60 minutes per session, 40 sessions over 8–10 weeks.
Wound healing & diabetic foot ulcers: the best-established indication
A meta-analysis of 14 controlled studies (768 participants, 12 RCTs) found adjunctive HBOT significantly improved complete healing of diabetic foot ulcers (OR 0.29 favoring HBOT) and reduced major amputation by roughly 40% (RR 0.60; 95% CI 0.39–0.92)[5]. It found no significant benefit for minor amputation and a modestly higher rate of largely benign adverse events.
Diabetic foot ulcer outcomes with adjunctive HBOT
Relative risk vs. standard care alone. Values below 1.0 favor HBOT.[5]
Long COVID: a cautionary result
The 2025 HOT-LoCO phase II RCT delivered 10 sessions of hyperbaric oxygen versus sham. At 13 weeks, both groups improved, but there was no statistically significant difference in physical functioning[6]. Dose and indication matter.
Longevity & the aging brain
The longevity rationale rests on earlier controlled work showing repeated sessions can lengthen telomeres and reduce senescent-cell burden in older adults[4]. These findings remain preliminary — a promising adjunct under active investigation, not an established anti-aging cure.
| Indication | Evidence (2026) | Typical protocol |
|---|---|---|
| Diabetic foot ulcer / wounds | Established (meta-analytic) | 2.0–2.5 ATA · 20–40 sessions |
| TBI / post-concussion | Emerging, RCT-supported | 1.5–2.0 ATA · 40 sessions |
| Cognition / longevity | Preliminary | 1.5–2.0 ATA · 40–60 sessions |
| Long COVID | Mixed / inconclusive | 2.0–2.4 ATA · 10–40 sessions |
The main absolute contraindication is untreated pneumothorax; relative cautions include certain chemotherapy agents, severe COPD, recent ear/sinus surgery and uncontrolled seizures. Most adverse events are mild and reversible.
For practitioners
HBOT has graduated from fringe to a legitimate, evidence-graded intervention whose value depends on matching the right protocol to the right indication. As always, the dose is the drug.
References
- HBOT improves post-concussion symptoms in adults with childhood TBI: retrospective cohort. 2025. View source
- HBOT for neurocognitive deficits in TBI: systematic review and meta-analysis. Neurology. View source
- Double-blind sham-controlled RCT of HBOT for TBI/PTSD in veterans. 2025. View source
- Mechanistic/longevity effects of HBOT (telomere, senescent cells, cerebral blood flow). View source
- Efficacy of HBOT for diabetic foot ulcer: meta-analysis (14 studies, 768 participants). View source
- Ten sessions of HBOT vs sham in long COVID (HOT-LoCO): phase II RCT. 2025. View source
This article is for educational purposes and summarizes published research; several findings are preliminary. It is not medical advice. Please consult a qualified healthcare provider before starting hyperbaric oxygen therapy.